CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 9 enrolled
Drug / intervention
AlloDerm RTU +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01781299
NCT01781299Phase 4Completed
CompareCT.gov

Acellular Dermal Matrix in Tissue Expander Breast Reconstruction: A Prospective, Randomized, Clinical Trial Comparing SurgiMend PRS and AlloDerm RTU

University of Pittsburgh·interventional·Posted Jan 31, 2013·Updated May 12, 2017

In Brief

A Phase 4 clinical trial evaluating AlloDerm RTU and SurgiMend PRS for Breast Cancer and Mastectomy. Completed, enrolled 9 participants across 1 site.

Detailed Summary

The purpose of this study is to assess the relative performance and complication rates between the AlloDerm RTU and SurgiMend PRS products as well as the relative economics of these two treatment options.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer, Mastectomy
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJan 31, 2013
Enrollment StartSep 1, 2012
Primary CompletionSep 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 13.4 years ago

Interventions

AlloDerm RTUdevice

SurgiMend PRSdevice